# Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study

> **NCT03381274** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **MedImmune LLC** · enrollment: 43 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **BIOLOGICAL:** Oleclumab
- **DRUG:** Osimertinib
- **DRUG:** AZD4635

## Key facts

- **NCT ID:** NCT03381274
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-05-08
- **Primary completion:** 2021-05-24
- **Final completion:** 2026-04-16
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2026-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03381274

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03381274, "Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT03381274. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*